Latest On Enanta Pharmaceuticals, Inc (ENTA):
| Date/Time | Type | Description | Signal | Details |
|---|---|---|---|---|
| 2023-05-10 15:19 EST | News | Enanta Pharma GAAP EPS of -$1.79 beats by $0.45, revenue of $17.8M beats by $4.91M | N/A |  |
| 2023-05-08 23:22 EST | News | Enanta Pharma GAAP EPS of -$1.79 beats by $0.13, revenue of $17.8M misses by $1.26M | N/A | |
| 2023-05-08 23:21 EST | News | Enanta Pharma Q2 2023 Earnings Preview | N/A | |
| 2023-05-08 23:21 EST | News | Enanta falls 21% as fiscal 2023 Q2 revenue misses | N/A | |
| 2023-05-08 23:21 EST | News | Enanta Pharmaceuticals, Inc. (ENTA) Q2 2023 Earnings Call Transcript | N/A | |
| 2023-05-07 21:30 EST | News | Enanta Pharma FQ2 2023 Earnings Preview | N/A | |
| 2023-04-25 17:01 EST | News | Enanta Pharma sells portion of Mavyret royalties for $200M | N/A | |
| 2023-04-06 13:14 EST | News | Enanta RSV therapy EDP-323 gets FDA track status | N/A | |
| 2023-02-08 07:20 EST | News | Enanta Pharmaceuticals, Inc. (ENTA) Q1 2023 Earnings Call Transcript | N/A | |
| 2023-02-08 07:20 EST | News | Enanta Pharmaceuticals, Inc. 2023 Q1 - Results - Earnings Call Presentation | N/A | |
| 2023-02-07 18:44 EST | News | Enanta Pharma GAAP EPS of -$1.39 beats by $0.16, revenue of $23.6M beats by $1.12M | N/A | |
| 2023-02-07 05:43 EST | News | Enanta Pharma Q1 2023 Earnings Preview | N/A | |
| 2022-12-30 23:01 EST | News | Enanta: Deep Losses In FY 2022 Look To Be Justified Given Macro Landscape | N/A | |
| 2022-11-22 01:29 EST | News | Enanta Pharma GAAP EPS of -$1.27 beats by $0.07, revenue of $20.32M misses by $2.54M | N/A | |
| 2022-11-22 01:29 EST | News | Enanta Pharmaceuticals, Inc. (ENTA) Q4 2022 Earnings Call Transcript | N/A | |
| 2022-11-19 06:40 EST | News | Enanta Pharma Q4 2022 Earnings Preview | N/A | |
| 2022-11-09 23:31 EST | News | Enanta starts mid-stage study of oral antiviral EDP-235 for COVID-19 | N/A | |
| 2022-10-04 01:11 EST | News | Enanta starts mid-stage trial of EDP-938 for RSV infection | N/A | |
| 2022-08-09 01:51 EST | News | Enanta Pharma GAAP EPS of -$1.53 misses by $0.16, revenue of $19.48M misses by $1.25M | N/A | |
| 2022-08-09 01:50 EST | News | Enanta Pharmaceuticals, Inc. (ENTA) CEO Jay Luly on Q3 2022 Results - Earnings Call Transcript | N/A | |
| 2022-08-07 23:45 EST | News | Enanta Pharma FQ3 2022 Earnings Preview | N/A | |
| 2022-07-29 12:44 EST | News | Enanta potential COVID drug shows safety in healthy people in early-stage trial | N/A | |
| 2022-06-22 19:06 EST | News | Enanta files patent infringement lawsuit against Pfizer over Paxlovid | N/A | |
| 2022-05-19 01:57 EST | News | Enanta Pharma says phase 2b study evaluating EDP-938 did not meet main goal | N/A | |
| 2022-05-18 06:15 EST | News | Enanta: Slow Drip | N/A | |
| 2022-05-10 05:10 EST | News | Enanta Pharma GAAP EPS of -$1.63 misses by $0.20, revenue of $18.72M misses by $1.95M | N/A | |
| 2022-05-10 05:10 EST | News | Enanta Pharmaceuticals, Inc. (ENTA) CEO Jay Luly on Q2 2022 Results - Earnings Call Transcript | N/A | |
| 2022-05-09 09:15 EST | News | Enanta Pharma Q2 2022 Earnings Preview | N/A | |
| 2022-03-30 00:55 EST | News | Enanta's oral drug EDP-235 for COVID-19 gets FDA fast track status | N/A | |
| 2022-02-16 18:33 EST | News | Enanta begins dosing of oral COVID-19 therapy EDP-235 in phase 1 trial | N/A | |
| 2022-02-09 10:52 EST | News | Enanta Pharmaceuticals, Inc. (ENTA) CEO Jay Luly on Q1 2022 Results - Earnings Call Transcript | N/A | |
| 2022-02-08 16:36 EST | News | Enanta Pharma GAAP EPS of -$1.48 misses by $0.37, revenue of $27.65M beats by $0.28M | N/A | |
| 2022-02-07 21:48 EST | News | Enanta Pharma Q1 2022 Earnings Preview | N/A | |
| 2022-01-13 14:35 EST | News | Enanta under pressure after SVB Leerink slashed price target | N/A | |
| 2022-01-07 04:16 EST | News | Enanta Pharmaceuticals rises on pipeline updates for 2022 | N/A | |
| 2021-12-03 13:12 EST | News | Enanta Pharmaceuticals, Inc. 2021 Q4 - Results - Earnings Call Presentation | N/A | |
| 2021-11-23 21:21 EST | News | Enanta adds more than a tenth, most in over a year after quarterly results | N/A | |
| 2021-11-22 23:28 EST | News | Enanta Pharma EPS beats by $0.06, misses on revenue | N/A | |
| 2021-11-22 23:28 EST | News | Enanta Pharmaceuticals, Inc. (ENTA) CEO Dr. Jay Luly on Q4 Fiscal 2021 Result - Earnings Call Transcript | N/A | |
| 2021-10-19 09:29 EST | News | Merck COVID-19 pill among antivirals WHO-led program plans to buy - Reuters | N/A | |
| 2021-10-19 09:29 EST | News | Enanta EDP-235 shows antiviral activity against COVID-19 in preclinical study | N/A | |
| 2021-10-19 09:29 EST | News | Merck rises as Atea slips in mid-stage trial for oral COVID-19 therapy | N/A | |
| 2021-10-07 09:31 EST | News | Enanta to present preclinical data for EDP-235 for COVID-19 at ISRIV-WHO conference | N/A | |
| 2021-10-02 10:11 EST | News | Enanta Pharma joins Merck’s COVID-pill rally to reach a record high | N/A | |
| 2021-09-21 17:14 EST | News | Enanta Pharmaceuticals (ENTA) Investor Presentation - Slideshow | N/A | |
| 2021-08-09 07:01 EST | News | Enanta Pharmaceuticals, Inc.'s (ENTA) CEO Jay Luly on Q3 2021 Results - Earnings Call Transcript | N/A | |
| 2021-08-06 02:10 EST | News | Enanta Pharma EPS beats by $0.16, misses on revenue | N/A | |
| 2021-08-05 03:56 EST | News | Enanta Pharma FQ3 2021 Earnings Preview | N/A | |
| 2021-07-21 06:36 EST | News | Enanta Pharmaceuticals posts data from early-stage study cohorts of EDP-514 | N/A | |
| 2021-07-21 06:35 EST | News | Enanta Pharma presents new EDP-721 data in HBV at EASL congress | N/A | |
About Enanta Pharmaceuticals, Inc (ENTA):
Enanta Pharmaceuticals, Inc., a biotechnology company, discovers and develops small molecule drugs for the treatment of viral infections and liver diseases. Its research and development disease targets include respiratory syncytial virus, non-alcoholic steatohepatitis, SARS-CoV-2, human metapneumovirus, and hepatitis B virus. The company offers glecaprevir for the treatment of chronic hepatitis C virus, or HCV under the MAVYRET and MAVIRET names. Enanta Pharmaceuticals, Inc. has a collaborative development and license agreement with Abbott Laboratories to identify, develop, and commercialize HCV NS3 and NS3/4A protease inhibitor compounds, including paritaprevir and glecaprevir for the treatment of chronic hepatitis C virus. The company was founded in 1995 and is headquartered in Watertown, Massachusetts.
General
- Name Enanta Pharmaceuticals, Inc
- Symbol ENTA
- Type Common Stock
- Exchange NASDAQ
- Currency USD
- Country USA
- SectorHealthcare
- IndustryBiotechnology
- Full Time Employees 141
- Fiscal Year EndSeptember
- IPO Date2013-03-21
- Gic SectorHealth Care
- Gic GroupPharmaceuticals, Biotechnology & Life Sciences
- Gic IndustryBiotechnology
- Gic SubIndustryBiotechnology
- Web URLhttp://www.enanta.com
View More
Valuation
- Trailing PE 436.7
- Price/Sales (Trailing 12 Mt.) 10.26
- Price/Book (Most Recent Quarter) 2.32
- Enterprise Value Revenue 6.62
- Enterprise Value EBITDA 40.19
View More
Financials
- Most Recent Quarter 2020-12-31
- Current Year EPS Estimate -$3.17
- Next Year EPS Estimate -$4.75
- Next Quarter EPS Estimate -$1.09
- Profit Margin -57%
- Operating Margin -66%
- Return on Assets -8%
- Return on Equity -12%
- Revenue 101.65 million
- Earnings Per Share $0.12
- Revenue Per Share $5.08
- Gross Profit 122.47 million
- Quarterly Earnings Growth -39.6%
View More
Highlights
- Market Capitalization 1.03 billion
- EBITDA 14.78 million
- PE Ratio -2.37
- Analyst Target Price $68.29
- Book Value Per Share $22.44
View More
Share Statistics
- Shares Outstanding 20.17 million
- Shares Float 13.83 million
- % Held by Insiders 1187%
- % Held by Institutions 95.3%
- Shares Short 2.16 million
- Shares Short Prior Month 2.13 million
- Short Ratio 13.85
- Short % of Float 14%
- Short % of Shares Outstanding 11%
View More
Technicals
- Beta 0.41
- 52 Week High $58.59
- 52 Week Low $40.32
- 50 Day Moving Average 51.4
- 200 Day Moving Average 46.6
View More
Dividends
- Dividend Date N/A
- ExDividend Date N/A
- Dividend Yield 0%
View More
Enanta Pharmaceuticals, Inc (ENTA) Dividend Calendar:
| Ex-Dividend Date | Payment Date | Record Date | Declared Date | Amount |
|---|
Enanta Pharmaceuticals, Inc (ENTA) Earnings History:
Companies typically report earnings on both a quarterly and annual basis. Earnings reported that deviate from analysts' expectations can have a large impact on a stock's price.
| Quarter Date | Report Date | Actual Revenue | Reported EPS | EPS Estimate | Deviation from Estimate |
|---|---|---|---|---|---|
| 2020-12-31 | 2021-02-08 | $31.74 million | -$0.41 | -$0.77 | 46.52% |
| 2020-09-30 | 2020-11-23 | $N/A | -$1.46 | -$0.97 | -50.01% |
| 2020-06-30 | 2020-08-04 | $18.65 million | -$0.71 | -$0.96 | 26.23% |
| 2020-03-31 | 2020-05-06 | $27.62 million | -$0.30 | -$0.72 | 58.1% |
| 2019-12-31 | 2020-02-06 | $52.57 million | $0.65 | $0.60 | 8.7% |
| 2019-09-30 | 2019-11-21 | $51.31 million | $0.44 | $0.56 | -20.72% |
| 2019-06-30 | 2019-08-06 | $44.37 million | $0.33 | $0.17 | 94.12% |
| 2019-03-31 | 2019-05-07 | $39.63 million | $0.20 | -$0.05 | 475.23% |
| 2018-12-31 | 2019-02-06 | $69.89 million | $1.25 | $1.29 | -2.72% |
| 2018-09-30 | 2018-11-26 | $67.21 million | $1.30 | $1.11 | 17.65% |
| 2018-06-30 | 2018-08-07 | $57.26 million | $0.97 | $0.90 | 7.38% |
| 2018-03-31 | 2018-05-08 | $44.05 million | $0.61 | $0.25 | 148.98% |
| 2017-12-31 | 2018-02-07 | $38.11 million | $0.40 | $0.27 | 49.98% |
| 2017-09-30 | 2017-11-20 | $75.93 million | $1.86 | $2.13 | -12.76% |
| 2017-06-30 | 2017-08-07 | $7.51 million | -$0.44 | -$0.48 | 8.05% |
| 2017-03-31 | 2017-05-08 | $8.96 million | -$0.28 | -$0.38 | 26.95% |
| 2016-12-31 | 2017-02-08 | $10.42 million | -$0.26 | -$0.18 | -41.46% |
| 2016-09-30 | 2016-11-21 | $12.84 million | -$0.09 | -$0.18 | 50% |
| 2016-06-30 | 2016-08-08 | $13.98 million | -$0.06 | -$0.09 | 36.58% |
| 2016-03-31 | 2016-05-09 | $13 million | -$0.09 | $0.14 | -163.83% |
| 2015-12-31 | 2016-02-08 | $48.45 million | $1.36 | $1.13 | 20.1% |
| 2015-09-30 | 2015-11-23 | $14.42 million | $0.29 | $0.15 | 93.33% |
| 2015-06-30 | 2015-08-06 | $11.6 million | $0.13 | $0.19 | -31.58% |
| 2015-03-31 | 2015-05-07 | $57.37 million | $1.49 | $1.76 | -15.34% |
| 2014-12-31 | 2015-02-05 | $77.5 million | $2.18 | $3.82 | -42.93% |
| 2014-09-30 | 2014-11-24 | $2.64 million | -$0.27 | -$0.33 | 18.18% |
| 2014-06-30 | 2014-08-11 | $42.05 million | $1.82 | $1.67 | 8.98% |
| 2014-03-31 | 2014-05-12 | $2.16 million | -$0.28 | $0.08 | -450% |
| 2013-12-31 | 2014-02-13 | $893000 | -$0.30 | -$0.29 | -3.45% |
| 2013-09-30 | 2013-11-25 | $1.35 million | -$0.25 | -$0.29 | 13.79% |
| 2013-06-30 | 2013-08-12 | $1.65 million | -$0.23 | -$0.33 | 30.3% |
| 2013-03-31 | 2013-05-08 | $1.2 million | -$2.28 | -$0.33 | -590.91% |
Enanta Pharmaceuticals, Inc (ENTA) Company Financial Statements:
Financial statements are reports prepared by a company's management to present their financial performance and position at a point in time. A general-purpose set of financial statements usually includes a balance sheet, income statements, and statement of cash flows.
Income Statement:
| Date |
|---|
| Research Development |
| Income Before Tax |
| Selling General Administrative |
| Gross Profit |
| Ebit |
| Operating Income |
| Income Tax Expense |
| Total Revenue |
| Cost of Revenue |
| Total Other Income Expense Net |
| Net Income From Continuing Operations |
| Net Income Applicable to Common Shares |
Cash Flow:
| Date |
|---|
| Investments |
| Change to Liabilities |
| Total Cash Flow from Investing Activities |
| Net Borrowings |
| Total Cash Flow from Financial Activities |
| Change to Operating Activities |
| Change in Cash |
| Total Cash from Operating Activities |
| Depreciation |
| Other Cash Flow from Investing Activities |
| Change to Inventory |
| Change to Account Receivables |
| Other Cash Flow from Financing Activities |
| Change to Net Income |
| Capital Expenditures |
Balance Sheet:
| Date |
|---|
| Total Liabailities |
| Total Stockholder Equity |
| Other Current Liabilities |
| Total Assets |
| Common Stock |
| Other Current Assets |
| Retained Earnings |
| Other Liabilities |
| Other Assets |
| Cash |
| Total Current Liabilities |
| Other Stockholder Equity |
| Property, Plant & Equipment |
| Total Current Assets |
| Long Term Investments |
| Net Tangible Assets |
| Short Term Investments |
| Long Term Debt |
| Inventory |
| Accounts Payable |
Enanta Pharmaceuticals, Inc (ENTA) Chart:
Enanta Pharmaceuticals, Inc (ENTA) News:
Below you will find a list of latest news for Enanta Pharmaceuticals, Inc (ENTA) from major news sources. You can filter the results to only show news from a specific source.
No recent news available
Enanta Pharmaceuticals, Inc (ENTA) Options:
A stock option is a contract between two parties in which the stock option buyer (holder) purchases the right (but not the obligation) to buy/sell 100 shares of an underlying stock at a predetermined price from/to the option seller (writer) within a fixed period of time.
| Expiration Date | Strike | Last Price | Type | Volume | Open Interest | Implied Volatility | In The Money | Change | Change Percent |
|---|---|---|---|---|---|---|---|---|---|
| 2025-05-16 | 2.5 | 0 | CALL | 0 | 0 | 616.88 | TRUE | 0 | 0 |
| 2025-05-16 | 5 | 0.5 | CALL | 0 | 3 | 865.5 | TRUE | 0 | 0 |
| 2025-05-16 | 7.5 | 0.05 | CALL | 0 | 3 | 363.7 | FALSE | 0 | 0 |
| 2025-05-16 | 10 | 0.05 | CALL | 0 | 1 | 499.27 | FALSE | 0 | 0 |
| 2025-05-16 | 2.5 | 0.05 | PUT | 0 | 93 | 333.62 | FALSE | 0 | 0 |
| 2025-05-16 | 5 | 0.15 | PUT | 0 | 19 | 141.41 | FALSE | 0 | 0 |
| 2025-05-16 | 7.5 | 0 | PUT | 0 | 0 | 352.77 | TRUE | 0 | 0 |
| 2025-05-16 | 10 | 0 | PUT | 0 | 0 | 320.03 | TRUE | 0 | 0 |
| 2025-06-20 | 2.5 | 0 | CALL | 0 | 0 | 290.96 | TRUE | 0 | 0 |
| 2025-06-20 | 5 | 1.1 | CALL | 0 | 1 | 82.87 | TRUE | 0 | 0 |
| 2025-06-20 | 7.5 | 0.39 | CALL | 0 | 1 | 107.73 | FALSE | 0 | 0 |
| 2025-06-20 | 10 | 0 | CALL | 0 | 0 | 166.49 | FALSE | 0 | 0 |
| 2025-06-20 | 2.5 | 0.05 | PUT | 0 | 6 | 277.32 | FALSE | 0 | 0 |
| 2025-06-20 | 5 | 0.5 | PUT | 0 | 18 | 78.06 | FALSE | 0 | 0 |
| 2025-06-20 | 7.5 | 0 | PUT | 0 | 0 | 129.95 | TRUE | 0 | 0 |
| 2025-06-20 | 10 | 0 | PUT | 0 | 0 | 266.89 | TRUE | 0 | 0 |
| 2025-07-18 | 2.5 | 2.8 | CALL | 0 | 1 | 691.55 | TRUE | 0 | 0 |
| 2025-07-18 | 5 | 0.85 | CALL | 0 | 155 | 89.03 | TRUE | 0 | 0 |
| 2025-07-18 | 7.5 | 0.4 | CALL | 6 | 307 | 109.2 | FALSE | 0.4 | 0 |
| 2025-07-18 | 10 | 0.65 | CALL | 0 | 50 | 119.68 | FALSE | 0 | 0 |
| 2025-07-18 | 12.5 | 0 | CALL | 0 | 0 | 135.32 | FALSE | 0 | 0 |
| 2025-07-18 | 15 | 0 | CALL | 0 | 0 | 209.09 | FALSE | 0 | 0 |
| 2025-07-18 | 17.5 | 0 | CALL | 0 | 0 | 226.24 | FALSE | 0 | 0 |
| 2025-07-18 | 20 | 0 | CALL | 0 | 0 | 468.71 | FALSE | 0 | 0 |
| 2025-07-18 | 2.5 | 0 | PUT | 0 | 0 | 214.44 | FALSE | 0 | 0 |
| 2025-07-18 | 5 | 1.15 | PUT | 0 | 38 | 72.58 | FALSE | 0 | 0 |
| 2025-07-18 | 7.5 | 1.47 | PUT | 0 | 9 | 102.12 | TRUE | 0 | 0 |
| 2025-07-18 | 10 | 0 | PUT | 0 | 0 | 89.01 | TRUE | 0 | 0 |
| 2025-07-18 | 12.5 | 0 | PUT | 0 | 0 | 151.61 | TRUE | 0 | 0 |
| 2025-07-18 | 15 | 0 | PUT | 0 | 0 | 132.74 | TRUE | 0 | 0 |
| 2025-07-18 | 17.5 | 0 | PUT | 0 | 0 | 238.57 | TRUE | 0 | 0 |
| 2025-07-18 | 20 | 0 | PUT | 0 | 0 | 194.93 | TRUE | 0 | 0 |
| 2025-10-17 | 2.5 | 0 | CALL | 0 | 0 | 175.38 | TRUE | 0 | 0 |
| 2025-10-17 | 5 | 1.3 | CALL | 0 | 21 | 87.48 | TRUE | 0 | 0 |
| 2025-10-17 | 7.5 | 0.8 | CALL | 10 | 458 | 100.89 | FALSE | 0.8 | 0 |
| 2025-10-17 | 10 | 0.66 | CALL | 0 | 54 | 97.36 | FALSE | 0 | 0 |
| 2025-10-17 | 12.5 | 0 | CALL | 0 | 0 | 163.9 | FALSE | 0 | 0 |
| 2025-10-17 | 2.5 | 0 | PUT | 0 | 0 | 282.08 | FALSE | 0 | 0 |
| 2025-10-17 | 5 | 1.44 | PUT | 0 | 30 | 60.87 | FALSE | 0 | 0 |
| 2025-10-17 | 7.5 | 1.25 | PUT | 0 | 8 | 82.79 | TRUE | 0 | 0 |
| 2025-10-17 | 10 | 0 | PUT | 0 | 0 | 97.13 | TRUE | 0 | 0 |
| 2025-10-17 | 12.5 | 0 | PUT | 0 | 0 | 143.58 | TRUE | 0 | 0 |
Latest ENTA Trades:
| Date | Shares | Price |
|---|---|---|
| Jun 13, 2022 7:59 PM EST | 50 | $39.71 |
| Jun 13, 2022 7:59 PM EST | 140 | $39.7 |
| Jun 13, 2022 7:59 PM EST | 61 | $39.74 |
| Jun 13, 2022 7:59 PM EST | 30 | $39.74 |
| Jun 13, 2022 7:59 PM EST | 1 | $39.71 |
Enanta Pharmaceuticals, Inc (ENTA) SEC Filings:
An SEC filing is a financial statement or other formal document submitted to the U.S. Securities and Exchange Commission (SEC). Public companies, certain insiders, and broker-dealers are required to make regular SEC filings.
| Date | Form Type | Form Name | Link |
|---|---|---|---|
| 2020-07-01 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1177648/000117764820000029/0001177648-20-000029-index.htm |
| 2019-02-14 | SC 13G | Statement of acquisition of beneficial ownership by individuals | https://www.sec.gov/Archives/edgar/data/1177648/000008025519002633/0000080255-19-002633-index.htm |
| 2020-02-14 | SC 13G/A | Statement of acquisition of beneficial ownership by individuals | https://www.sec.gov/Archives/edgar/data/1177648/000008025520001241/0000080255-20-001241-index.htm |
| 2019-01-28 | SC 13G/A | Statement of acquisition of beneficial ownership by individuals | https://www.sec.gov/Archives/edgar/data/1177648/000021545719001541/0000215457-19-001541-index.htm |
| 2020-02-04 | SC 13G/A | Statement of acquisition of beneficial ownership by individuals | https://www.sec.gov/Archives/edgar/data/1177648/000083423720001638/0000834237-20-001638-index.htm |
| 2019-02-11 | SC 13G | Statement of acquisition of beneficial ownership by individuals | https://www.sec.gov/Archives/edgar/data/1177648/000093247119005297/0000932471-19-005297-index.htm |
| 2020-01-23 | SC 13G/A | Statement of acquisition of beneficial ownership by individuals | https://www.sec.gov/Archives/edgar/data/1177648/000110465920006199/0001104659-20-006199-index.htm |
| 2020-02-12 | SC 13G/A | Statement of acquisition of beneficial ownership by individuals | https://www.sec.gov/Archives/edgar/data/1177648/000110465920018170/0001104659-20-018170-index.htm |
| 2019-02-08 | SC 13G/A | Statement of acquisition of beneficial ownership by individuals | https://www.sec.gov/Archives/edgar/data/1177648/000114420419005714/0001144204-19-005714-index.htm |
| 2018-03-05 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1177648/000117764818000009/0001177648-18-000009-index.htm |
| 2018-03-05 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1177648/000117764818000011/0001177648-18-000011-index.htm |
| 2018-03-05 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1177648/000117764818000013/0001177648-18-000013-index.htm |
| 2018-03-05 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1177648/000117764818000015/0001177648-18-000015-index.htm |
| 2018-03-05 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1177648/000117764818000017/0001177648-18-000017-index.htm |
| 2018-03-05 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1177648/000117764818000019/0001177648-18-000019-index.htm |
| 2018-03-20 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1177648/000117764818000020/0001177648-18-000020-index.htm |
| 2018-04-18 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1177648/000117764818000022/0001177648-18-000022-index.htm |
| 2018-05-18 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1177648/000117764818000024/0001177648-18-000024-index.htm |
| 2018-05-18 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1177648/000117764818000026/0001177648-18-000026-index.htm |
| 2018-06-12 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1177648/000117764818000027/0001177648-18-000027-index.htm |
| 2018-06-19 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1177648/000117764818000028/0001177648-18-000028-index.htm |
| 2018-06-20 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1177648/000117764818000029/0001177648-18-000029-index.htm |
| 2018-07-09 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1177648/000117764818000030/0001177648-18-000030-index.htm |
| 2018-07-19 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1177648/000117764818000031/0001177648-18-000031-index.htm |
| 2018-07-30 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1177648/000117764818000032/0001177648-18-000032-index.htm |
| 2018-08-21 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1177648/000117764818000033/0001177648-18-000033-index.htm |
| 2018-09-21 | 4/A | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1177648/000117764818000034/0001177648-18-000034-index.htm |
| 2018-09-21 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1177648/000117764818000035/0001177648-18-000035-index.htm |
| 2018-10-02 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1177648/000117764818000036/0001177648-18-000036-index.htm |
| 2018-10-02 | 4/A | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1177648/000117764818000037/0001177648-18-000037-index.htm |
| 2018-10-02 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1177648/000117764818000038/0001177648-18-000038-index.htm |
| 2018-11-20 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1177648/000117764818000040/0001177648-18-000040-index.htm |
| 2018-11-20 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1177648/000117764818000042/0001177648-18-000042-index.htm |
| 2018-11-20 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1177648/000117764818000044/0001177648-18-000044-index.htm |
| 2018-11-20 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1177648/000117764818000046/0001177648-18-000046-index.htm |
| 2018-11-20 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1177648/000117764818000048/0001177648-18-000048-index.htm |
| 2018-11-20 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1177648/000117764818000050/0001177648-18-000050-index.htm |
| 2018-12-04 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1177648/000117764818000051/0001177648-18-000051-index.htm |
| 2018-12-06 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1177648/000117764818000053/0001177648-18-000053-index.htm |
| 2019-01-24 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1177648/000117764819000001/0001177648-19-000001-index.htm |
| 2019-02-13 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1177648/000117764819000003/0001177648-19-000003-index.htm |
| 2019-02-13 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1177648/000117764819000005/0001177648-19-000005-index.htm |
| 2019-02-13 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1177648/000117764819000007/0001177648-19-000007-index.htm |
| 2019-02-13 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1177648/000117764819000009/0001177648-19-000009-index.htm |
| 2019-02-13 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1177648/000117764819000011/0001177648-19-000011-index.htm |
| 2019-02-13 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1177648/000117764819000013/0001177648-19-000013-index.htm |
| 2019-02-13 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1177648/000117764819000015/0001177648-19-000015-index.htm |
| 2019-02-13 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1177648/000117764819000017/0001177648-19-000017-index.htm |
| 2019-02-25 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1177648/000117764819000018/0001177648-19-000018-index.htm |
| 2019-03-01 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1177648/000117764819000019/0001177648-19-000019-index.htm |
| 2019-03-01 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1177648/000117764819000020/0001177648-19-000020-index.htm |
| 2019-03-01 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1177648/000117764819000021/0001177648-19-000021-index.htm |
| 2019-03-01 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1177648/000117764819000022/0001177648-19-000022-index.htm |
| 2019-03-01 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1177648/000117764819000023/0001177648-19-000023-index.htm |
| 2019-03-01 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1177648/000117764819000024/0001177648-19-000024-index.htm |
| 2019-03-04 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1177648/000117764819000025/0001177648-19-000025-index.htm |
| 2019-03-06 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1177648/000117764819000028/0001177648-19-000028-index.htm |
| 2019-03-07 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1177648/000117764819000030/0001177648-19-000030-index.htm |
| 2019-03-12 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1177648/000117764819000032/0001177648-19-000032-index.htm |
| 2019-06-26 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1177648/000117764819000033/0001177648-19-000033-index.htm |
| 2019-09-30 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1177648/000117764819000034/0001177648-19-000034-index.htm |
| 2019-10-09 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1177648/000117764819000035/0001177648-19-000035-index.htm |
| 2019-11-18 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1177648/000117764819000036/0001177648-19-000036-index.htm |
| 2019-11-18 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1177648/000117764819000037/0001177648-19-000037-index.htm |
| 2019-11-18 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1177648/000117764819000038/0001177648-19-000038-index.htm |
| 2019-11-18 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1177648/000117764819000039/0001177648-19-000039-index.htm |
| 2019-11-18 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1177648/000117764819000040/0001177648-19-000040-index.htm |
| 2019-11-25 | 4/A | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1177648/000117764819000041/0001177648-19-000041-index.htm |
| 2019-11-25 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1177648/000117764819000042/0001177648-19-000042-index.htm |
| 2020-01-06 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1177648/000117764820000001/0001177648-20-000001-index.htm |
| 2020-01-06 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1177648/000117764820000002/0001177648-20-000002-index.htm |
| 2020-01-06 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1177648/000117764820000003/0001177648-20-000003-index.htm |
| 2020-01-06 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1177648/000117764820000004/0001177648-20-000004-index.htm |
| 2020-01-06 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1177648/000117764820000005/0001177648-20-000005-index.htm |
| 2020-02-18 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1177648/000117764820000006/0001177648-20-000006-index.htm |
| 2020-02-18 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1177648/000117764820000007/0001177648-20-000007-index.htm |
| 2020-02-18 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1177648/000117764820000008/0001177648-20-000008-index.htm |
| 2020-02-18 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1177648/000117764820000009/0001177648-20-000009-index.htm |
| 2020-02-18 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1177648/000117764820000010/0001177648-20-000010-index.htm |
| 2020-02-28 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1177648/000117764820000012/0001177648-20-000012-index.htm |
| 2020-02-28 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1177648/000117764820000014/0001177648-20-000014-index.htm |
| 2020-02-28 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1177648/000117764820000016/0001177648-20-000016-index.htm |
| 2020-02-28 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1177648/000117764820000018/0001177648-20-000018-index.htm |
| 2020-02-28 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1177648/000117764820000020/0001177648-20-000020-index.htm |
| 2020-03-16 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1177648/000117764820000022/0001177648-20-000022-index.htm |
| 2020-05-07 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1177648/000117764820000024/0001177648-20-000024-index.htm |
| 2020-07-01 | 3 | Initial statement of beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1177648/000117764820000027/0001177648-20-000027-index.htm |
| 2020-07-01 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1177648/000117764820000029/0001177648-20-000029-index.htm |
| 2020-08-06 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1177648/000117764820000031/0001177648-20-000031-index.htm |
| 2018-11-26 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1177648/000119312518333906/0001193125-18-333906-index.htm |
| 2019-01-18 | DEF 14A | Other definitive proxy statements | https://www.sec.gov/Archives/edgar/data/1177648/000119312519012894/0001193125-19-012894-index.htm |
| 2019-01-18 | SC 13D | General statement of acquisition of beneficial ownership | https://www.sec.gov/Archives/edgar/data/1177648/000119312519012904/0001193125-19-012904-index.htm |
| 2019-01-18 | DEFA14A | Additional definitive proxy soliciting materials and Rule 14(a)(12) material | https://www.sec.gov/Archives/edgar/data/1177648/000119312519012909/0001193125-19-012909-index.htm |
| 2020-01-17 | DEF 14A | Other definitive proxy statements | https://www.sec.gov/Archives/edgar/data/1177648/000119312520010035/0001193125-20-010035-index.htm |
| 2020-01-17 | DEFA14A | Additional definitive proxy soliciting materials and Rule 14(a)(12) material | https://www.sec.gov/Archives/edgar/data/1177648/000119312520010040/0001193125-20-010040-index.htm |
| 2020-02-06 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1177648/000119312520026785/0001193125-20-026785-index.htm |
| 2020-02-13 | SC 13G/A | Statement of acquisition of beneficial ownership by individuals | https://www.sec.gov/Archives/edgar/data/1177648/000119312520034700/0001193125-20-034700-index.htm |
| 2020-03-04 | SC 13D/A | General statement of acquisition of beneficial ownership | https://www.sec.gov/Archives/edgar/data/1177648/000119312520061622/0001193125-20-061622-index.htm |
| 2018-05-10 | SC 13G | Statement of acquisition of beneficial ownership by individuals | https://www.sec.gov/Archives/edgar/data/1177648/000121465918003559/0001214659-18-003559-index.htm |
| 2019-02-14 | SC 13G/A | Statement of acquisition of beneficial ownership by individuals | https://www.sec.gov/Archives/edgar/data/1177648/000121465919001111/0001214659-19-001111-index.htm |
| 2019-09-27 | SC 13G | Statement of acquisition of beneficial ownership by individuals | https://www.sec.gov/Archives/edgar/data/1177648/000121465919006069/0001214659-19-006069-index.htm |
| 2020-02-14 | SC 13G/A | Statement of acquisition of beneficial ownership by individuals | https://www.sec.gov/Archives/edgar/data/1177648/000121465920001396/0001214659-20-001396-index.htm |
| 2018-05-08 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1177648/000156459018011793/0001564590-18-011793-index.htm |
| 2018-05-10 | 10-Q | Quarterly report [Sections 13 or 15(d)] | https://www.sec.gov/Archives/edgar/data/1177648/000156459018012940/0001564590-18-012940-index.htm |
| 2018-08-07 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1177648/000156459018019922/0001564590-18-019922-index.htm |
| 2018-08-09 | 10-Q | Quarterly report [Sections 13 or 15(d)] | https://www.sec.gov/Archives/edgar/data/1177648/000156459018021062/0001564590-18-021062-index.htm |
| 2018-11-29 | 10-K | Annual report [Section 13 and 15(d), not S-K Item 405] | https://www.sec.gov/Archives/edgar/data/1177648/000156459018030275/0001564590-18-030275-index.htm |
| 2019-02-06 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1177648/000156459019002137/0001564590-19-002137-index.htm |
| 2019-02-08 | 10-Q | Quarterly report [Sections 13 or 15(d)] | https://www.sec.gov/Archives/edgar/data/1177648/000156459019002428/0001564590-19-002428-index.htm |
| 2019-03-06 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1177648/000156459019006516/0001564590-19-006516-index.htm |
| 2019-03-07 | 8-K/A | Current report | https://www.sec.gov/Archives/edgar/data/1177648/000156459019006792/0001564590-19-006792-index.htm |
| 2019-05-07 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1177648/000156459019016489/0001564590-19-016489-index.htm |
| 2019-05-10 | 10-Q | Quarterly report [Sections 13 or 15(d)] | https://www.sec.gov/Archives/edgar/data/1177648/000156459019018517/0001564590-19-018517-index.htm |
| 2019-05-10 | S-8 | Securities to be offered to employees in employee benefit plans | https://www.sec.gov/Archives/edgar/data/1177648/000156459019018545/0001564590-19-018545-index.htm |
| 2019-05-10 | S-8 | Securities to be offered to employees in employee benefit plans | https://www.sec.gov/Archives/edgar/data/1177648/000156459019018571/0001564590-19-018571-index.htm |
| 2019-08-06 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1177648/000156459019029335/0001564590-19-029335-index.htm |
| 2019-08-09 | 10-Q | Quarterly report [Sections 13 or 15(d)] | https://www.sec.gov/Archives/edgar/data/1177648/000156459019031249/0001564590-19-031249-index.htm |
| 2019-11-21 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1177648/000156459019044095/0001564590-19-044095-index.htm |
| 2019-11-27 | 10-K | Annual report [Section 13 and 15(d), not S-K Item 405] | https://www.sec.gov/Archives/edgar/data/1177648/000156459019044729/0001564590-19-044729-index.htm |
| 2020-02-10 | 10-Q | Quarterly report [Sections 13 or 15(d)] | https://www.sec.gov/Archives/edgar/data/1177648/000156459020004041/0001564590-20-004041-index.htm |
| 2020-03-02 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1177648/000156459020008143/0001564590-20-008143-index.htm |
| 2020-05-06 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1177648/000156459020021925/0001564590-20-021925-index.htm |
| 2020-05-11 | 10-Q | Quarterly report [Sections 13 or 15(d)] | https://www.sec.gov/Archives/edgar/data/1177648/000156459020024177/0001564590-20-024177-index.htm |
| 2020-06-30 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1177648/000156459020031261/0001564590-20-031261-index.htm |
| 2020-08-04 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1177648/000156459020036125/0001564590-20-036125-index.htm |
| 2020-08-10 | 10-Q | Quarterly report [Sections 13 or 15(d)] | https://www.sec.gov/Archives/edgar/data/1177648/000156459020038908/0001564590-20-038908-index.htm |
| 2019-02-11 | SC 13G/A | Statement of acquisition of beneficial ownership by individuals | https://www.sec.gov/Archives/edgar/data/1177648/000156761919002908/0001567619-19-002908-index.htm |
Enanta Pharmaceuticals, Inc (ENTA) Insider Transactions:
Here you will find a list of insider trading activities (stock purchases, sales, and option exercises) reported by insiders of Enanta Pharmaceuticals, Inc (ENTA). Company insiders might sell their shares for any number of reasons, but they buy them for only one: they think the price will rise.Insider Ownership: 1187%Institutional Ownership: 9530%
| Transaction Date | Insider Name | Insider Title | Type | Shares Number | Shares Price | Total Transaction | Shares Held After Transaction | Link |
|---|---|---|---|---|---|---|---|---|
| 2019-02-11 | BRUCE L A CARTER | Director | Sell | 2,734.00 | 90.02 | 246,101.83 | 0.00 | https://www.sec.gov/Archives/edgar/data/1177648/000117764819000003/0001177648-19-000003-index.htm |
| 2019-02-12 | BRUCE L A CARTER | Director | Sell | 5,000.00 | 90.00 | 450,000.00 | 0.00 | https://www.sec.gov/Archives/edgar/data/1177648/000117764819000003/0001177648-19-000003-index.htm |
| 2019-03-11 | BRUCE L A CARTER | Director | Sell | 1,546.00 | 99.16 | 153,301.36 | 0.00 | https://www.sec.gov/Archives/edgar/data/1177648/000117764819000032/0001177648-19-000032-index.htm |
| 2019-02-11 | George Golumbeski | Director | Sell | 2,272.00 | 90.03 | 204,552.02 | 0.00 | https://www.sec.gov/Archives/edgar/data/1177648/000117764819000005/0001177648-19-000005-index.htm |
| 2019-02-12 | George Golumbeski | Director | Sell | 11,228.00 | 90.07 | 1,011,301.47 | 0.00 | https://www.sec.gov/Archives/edgar/data/1177648/000117764819000005/0001177648-19-000005-index.htm |
| 2019-03-04 | George Golumbeski | Director | Sell | 9,280.00 | 103.65 | 961,897.06 | 0.00 | https://www.sec.gov/Archives/edgar/data/1177648/000117764819000028/0001177648-19-000028-index.htm |
| 2018-09-20 | Nathalie Adda | Sr. VP & Chief Medical Officer | Sell | 1,371.00 | 96.89 | 132,841.95 | 0.00 | https://www.sec.gov/Archives/edgar/data/1177648/000117764818000035/0001177648-18-000035-index.htm |
| 2018-04-16 | Nathalie Adda | Sr. VP & Chief Medical Officer | Buy | 2,955.00 | 43.46 | 128,424.30 | 10,225.00 | https://www.sec.gov/Archives/edgar/data/1177648/000117764818000022/0001177648-18-000022-index.htm |
| 2019-02-12 | George Golumbeski | Director | Buy | 7,500.00 | 29.02 | 217,650.00 | 11,228.00 | https://www.sec.gov/Archives/edgar/data/1177648/000117764819000005/0001177648-19-000005-index.htm |
| 2019-02-12 | Tim Ocain | Senior Vice President | Buy | 4,000.00 | 12,127.00 | https://www.sec.gov/Archives/edgar/data/1177648/000117764819000017/0001177648-19-000017-index.htm | ||
| 2018-09-20 | Nathalie Adda | Sr. VP & Chief Medical Officer | Sell | 602.00 | 95.84 | 57,698.63 | 1,371.00 | https://www.sec.gov/Archives/edgar/data/1177648/000117764818000035/0001177648-18-000035-index.htm |
| 2020-02-12 | Nathalie Adda | Sr. VP & Chief Medical Officer | Buy | 487.00 | 13,800.00 | https://www.sec.gov/Archives/edgar/data/1177648/000117764820000009/0001177648-20-000009-index.htm | ||
| 2018-10-01 | Nathaniel S. Gardiner | Sr. VP & General Counsel | Buy | 1,500.00 | 34.70 | 52,050.00 | 13,827.00 | https://www.sec.gov/Archives/edgar/data/1177648/000117764818000036/0001177648-18-000036-index.htm |
| 2019-06-26 | Nathaniel S. Gardiner | Sr. VP & General Counsel | Buy | 3,295.00 | 31.42 | 103,528.90 | 14,871.00 | https://www.sec.gov/Archives/edgar/data/1177648/000117764819000033/0001177648-19-000033-index.htm |
| 2018-07-18 | Nathalie Adda | Sr. VP & Chief Medical Officer | Sell | 904.00 | 126.40 | 114,261.35 | 1,510.00 | https://www.sec.gov/Archives/edgar/data/1177648/000117764818000031/0001177648-18-000031-index.htm |
| 2019-03-11 | BRUCE L A CARTER | Director | Buy | 1,546.00 | 23.40 | 36,176.40 | 1,546.00 | https://www.sec.gov/Archives/edgar/data/1177648/000117764819000032/0001177648-19-000032-index.htm |
| 2019-12-16 | Nathalie Adda | Sr. VP & Chief Medical Officer | Buy | 5,250.00 | 15,644.00 | https://www.sec.gov/Archives/edgar/data/1177648/000117764820000004/0001177648-20-000004-index.htm | ||
| 2019-02-12 | Nathalie Adda | Sr. VP & Chief Medical Officer | Buy | 11,250.00 | 15,750.00 | https://www.sec.gov/Archives/edgar/data/1177648/000117764819000015/0001177648-19-000015-index.htm | ||
| 2018-12-06 | Nathaniel S. Gardiner | Sr. VP & General Counsel | Buy | 2,000.00 | 34.70 | 69,400.00 | 15,827.00 | https://www.sec.gov/Archives/edgar/data/1177648/000117764818000053/0001177648-18-000053-index.htm |
| 2020-02-12 | Nathalie Adda | Sr. VP & Chief Medical Officer | Buy | 2,925.00 | 16,725.00 | https://www.sec.gov/Archives/edgar/data/1177648/000117764820000009/0001177648-20-000009-index.htm | ||
| 2019-01-22 | Nathaniel S. Gardiner | Sr. VP & General Counsel | Buy | 2,000.00 | 34.70 | 69,400.00 | 17,827.00 | https://www.sec.gov/Archives/edgar/data/1177648/000117764819000001/0001177648-19-000001-index.htm |
| 2018-09-20 | Nathalie Adda | Sr. VP & Chief Medical Officer | Sell | 1,229.00 | 94.75 | 116,451.31 | 1,973.00 | https://www.sec.gov/Archives/edgar/data/1177648/000117764818000035/0001177648-18-000035-index.htm |
| 2019-11-22 | Nathaniel S. Gardiner | Sr. VP & General Counsel | Buy | 1,592.00 | 31.42 | 50,020.64 | 19,739.00 | https://www.sec.gov/Archives/edgar/data/1177648/000117764819000042/0001177648-19-000042-index.htm |
| 2019-09-27 | Nathaniel S. Gardiner | Sr. VP & General Counsel | Buy | 5,000.00 | 30.00 | 150,000.00 | 19,871.00 | https://www.sec.gov/Archives/edgar/data/1177648/000117764819000034/0001177648-19-000034-index.htm |
| 2018-10-01 | Tim Ocain | Senior Vice President | Buy | 15,000.00 | 19.98 | 299,700.00 | 21,127.00 | https://www.sec.gov/Archives/edgar/data/1177648/000117764818000038/0001177648-18-000038-index.htm |
| 2018-10-01 | Tim Ocain | Senior Vice President | Sell | 6,219.00 | 83.47 | 519,127.29 | 21,408.00 | https://www.sec.gov/Archives/edgar/data/1177648/000117764818000038/0001177648-18-000038-index.htm |
| 2019-02-12 | Nathaniel S. Gardiner | Sr. VP & General Counsel | Buy | 4,000.00 | 21,827.00 | https://www.sec.gov/Archives/edgar/data/1177648/000117764819000013/0001177648-19-000013-index.htm | ||
| 2019-02-12 | Tim Ocain | Senior Vice President | Buy | 10,000.00 | 22,127.00 | https://www.sec.gov/Archives/edgar/data/1177648/000117764819000017/0001177648-19-000017-index.htm | ||
| 2019-02-11 | George Golumbeski | Director | Buy | 2,272.00 | 25.58 | 58,117.76 | 2,272.00 | https://www.sec.gov/Archives/edgar/data/1177648/000117764819000005/0001177648-19-000005-index.htm |
| 2020-02-12 | Nathaniel S. Gardiner | Sr. VP & General Counsel | Buy | 412.00 | 23,070.00 | https://www.sec.gov/Archives/edgar/data/1177648/000117764820000010/0001177648-20-000010-index.htm | ||
| 2019-02-13 | Nathaniel S. Gardiner | Sr. VP & General Counsel | Sell | 3,270.00 | 95.28 | 311,562.33 | 23,978.00 | https://www.sec.gov/Archives/edgar/data/1177648/000117764819000013/0001177648-19-000013-index.htm |
| 2018-07-18 | Nathalie Adda | Sr. VP & Chief Medical Officer | Sell | 1,621.00 | 125.60 | 203,602.30 | 2,414.00 | https://www.sec.gov/Archives/edgar/data/1177648/000117764818000031/0001177648-18-000031-index.htm |
| 2019-12-16 | Nathaniel S. Gardiner | Sr. VP & General Counsel | Buy | 5,250.00 | 24,989.00 | https://www.sec.gov/Archives/edgar/data/1177648/000117764820000005/0001177648-20-000005-index.htm | ||
| 2020-02-12 | Nathaniel S. Gardiner | Sr. VP & General Counsel | Buy | 2,475.00 | 25,545.00 | https://www.sec.gov/Archives/edgar/data/1177648/000117764820000010/0001177648-20-000010-index.htm | ||
| 2019-03-06 | Nathaniel S. Gardiner | Sr. VP & General Counsel | Buy | 1,724.00 | 34.70 | 59,822.80 | 25,702.00 | https://www.sec.gov/Archives/edgar/data/1177648/000117764819000030/0001177648-19-000030-index.htm |
| 2019-03-06 | Nathaniel S. Gardiner | Sr. VP & General Counsel | Buy | 795.00 | 31.42 | 24,978.90 | 26,497.00 | https://www.sec.gov/Archives/edgar/data/1177648/000117764819000030/0001177648-19-000030-index.htm |
| 2019-02-11 | BRUCE L A CARTER | Director | Buy | 2,734.00 | 23.40 | 63,975.60 | 2,734.00 | https://www.sec.gov/Archives/edgar/data/1177648/000117764819000003/0001177648-19-000003-index.htm |
| 2020-03-12 | Nathaniel S. Gardiner | Sr. VP & General Counsel | Buy | 3,000.00 | 30.00 | 90,000.00 | 27,605.00 | https://www.sec.gov/Archives/edgar/data/1177648/000117764820000022/0001177648-20-000022-index.htm |
| 2018-10-01 | Tim Ocain | Senior Vice President | Sell | 3,500.00 | 82.04 | 287,142.10 | 27,627.00 | https://www.sec.gov/Archives/edgar/data/1177648/000117764818000038/0001177648-18-000038-index.htm |
| 2020-08-05 | Nathaniel S. Gardiner | Sr. VP & General Counsel | Buy | 1,666.00 | 30.00 | 49,980.00 | 29,271.00 | https://www.sec.gov/Archives/edgar/data/1177648/000117764820000031/0001177648-20-000031-index.htm |
| 2019-03-01 | Yat Sun Or | Sr. VP & CSO | Sell | 4,090.00 | 103.84 | 424,692.51 | 300,673.00 | https://www.sec.gov/Archives/edgar/data/1177648/000117764819000025/0001177648-19-000025-index.htm |
| 2019-02-12 | Yat Sun Or | Sr. VP & CSO | Sell | 6,297.00 | 90.07 | 567,173.31 | 301,916.00 | https://www.sec.gov/Archives/edgar/data/1177648/000117764819000007/0001177648-19-000007-index.htm |
| 2020-02-12 | Yat Sun Or | Sr. VP & CSO | Buy | 487.00 | 304,079.00 | https://www.sec.gov/Archives/edgar/data/1177648/000117764820000008/0001177648-20-000008-index.htm | ||
| 2019-03-01 | Yat Sun Or | Sr. VP & CSO | Sell | 5,910.00 | 103.32 | 610,627.70 | 304,763.00 | https://www.sec.gov/Archives/edgar/data/1177648/000117764819000025/0001177648-19-000025-index.htm |
| 2019-12-16 | Yat Sun Or | Sr. VP & CSO | Buy | 5,250.00 | 305,923.00 | https://www.sec.gov/Archives/edgar/data/1177648/000117764820000003/0001177648-20-000003-index.htm | ||
| 2019-02-12 | Yat Sun Or | Sr. VP & CSO | Buy | 4,500.00 | 306,416.00 | https://www.sec.gov/Archives/edgar/data/1177648/000117764819000007/0001177648-19-000007-index.htm | ||
| 2020-02-12 | Yat Sun Or | Sr. VP & CSO | Buy | 2,925.00 | 307,004.00 | https://www.sec.gov/Archives/edgar/data/1177648/000117764820000008/0001177648-20-000008-index.htm | ||
| 2019-02-11 | Yat Sun Or | Sr. VP & CSO | Sell | 171.00 | 91.24 | 15,601.70 | 308,213.00 | https://www.sec.gov/Archives/edgar/data/1177648/000117764819000007/0001177648-19-000007-index.htm |
| 2019-02-11 | Yat Sun Or | Sr. VP & CSO | Sell | 2,707.00 | 90.11 | 243,936.16 | 308,384.00 | https://www.sec.gov/Archives/edgar/data/1177648/000117764819000007/0001177648-19-000007-index.htm |
| 2018-08-20 | Nathalie Adda | Sr. VP & Chief Medical Officer | Sell | 659.00 | 93.49 | 61,612.61 | 310.00 | https://www.sec.gov/Archives/edgar/data/1177648/000117764818000033/0001177648-18-000033-index.htm |
| 2019-02-11 | Yat Sun Or | Sr. VP & CSO | Sell | 18,971.00 | 89.50 | 1,697,877.94 | 311,091.00 | https://www.sec.gov/Archives/edgar/data/1177648/000117764819000007/0001177648-19-000007-index.htm |
| 2018-10-01 | Tim Ocain | Senior Vice President | Buy | 10,000.00 | 32.27 | 322,700.00 | 31,127.00 | https://www.sec.gov/Archives/edgar/data/1177648/000117764818000038/0001177648-18-000038-index.htm |
| 2019-02-12 | Yat Sun Or | Sr. VP & CSO | Buy | 11,250.00 | 317,666.00 | https://www.sec.gov/Archives/edgar/data/1177648/000117764819000007/0001177648-19-000007-index.htm | ||
| 2019-02-12 | Nathaniel S. Gardiner | Sr. VP & General Counsel | Buy | 10,000.00 | 31,827.00 | https://www.sec.gov/Archives/edgar/data/1177648/000117764819000013/0001177648-19-000013-index.htm | ||
| 2018-08-20 | Nathalie Adda | Sr. VP & Chief Medical Officer | Sell | 700.00 | 91.49 | 64,042.02 | 3,193.00 | https://www.sec.gov/Archives/edgar/data/1177648/000117764818000033/0001177648-18-000033-index.htm |
| 2019-02-11 | Yat Sun Or | Sr. VP & CSO | Buy | 10,249.00 | 11.77 | 120,630.73 | 320,169.00 | https://www.sec.gov/Archives/edgar/data/1177648/000117764819000007/0001177648-19-000007-index.htm |
| 2018-09-20 | Nathalie Adda | Sr. VP & Chief Medical Officer | Sell | 453.00 | 93.90 | 42,535.11 | 3,202.00 | https://www.sec.gov/Archives/edgar/data/1177648/000117764818000035/0001177648-18-000035-index.htm |
| 2019-02-11 | Yat Sun Or | Sr. VP & CSO | Buy | 6,956.00 | 14.00 | 97,384.00 | 327,125.00 | https://www.sec.gov/Archives/edgar/data/1177648/000117764819000007/0001177648-19-000007-index.htm |
| 2019-02-11 | Yat Sun Or | Sr. VP & CSO | Sell | 5,835.00 | 88.66 | 517,321.18 | 330,062.00 | https://www.sec.gov/Archives/edgar/data/1177648/000117764819000007/0001177648-19-000007-index.htm |
| 2019-02-11 | Yat Sun Or | Sr. VP & CSO | Buy | 8,772.00 | 14.18 | 124,386.96 | 335,897.00 | https://www.sec.gov/Archives/edgar/data/1177648/000117764819000007/0001177648-19-000007-index.htm |
| 2018-06-18 | Nathalie Adda | Sr. VP & Chief Medical Officer | Sell | 658.00 | 115.89 | 76,253.91 | 3,600.00 | https://www.sec.gov/Archives/edgar/data/1177648/000117764818000028/0001177648-18-000028-index.htm |
| 2018-09-20 | Nathalie Adda | Sr. VP & Chief Medical Officer | Sell | 500.00 | 93.02 | 46,509.10 | 3,655.00 | https://www.sec.gov/Archives/edgar/data/1177648/000117764818000035/0001177648-18-000035-index.htm |
| 2019-02-12 | George Golumbeski | Director | Buy | 3,728.00 | 25.58 | 95,362.24 | 3,728.00 | https://www.sec.gov/Archives/edgar/data/1177648/000117764819000005/0001177648-19-000005-index.htm |
| 2018-08-20 | Nathalie Adda | Sr. VP & Chief Medical Officer | Sell | 572.00 | 90.58 | 51,811.65 | 3,893.00 | https://www.sec.gov/Archives/edgar/data/1177648/000117764818000033/0001177648-18-000033-index.htm |
| 2020-01-02 | PAUL J MELLETT | Treasurer and CFO | Sell | 721.00 | 61.66 | 44,458.23 | 40,054.00 | https://www.sec.gov/Archives/edgar/data/1177648/000117764820000001/0001177648-20-000001-index.htm |
| 2020-02-12 | PAUL J MELLETT | Treasurer and CFO | Buy | 225.00 | 40,279.00 | https://www.sec.gov/Archives/edgar/data/1177648/000117764820000007/0001177648-20-000007-index.htm | ||
| 2018-07-18 | Nathalie Adda | Sr. VP & Chief Medical Officer | Sell | 445.00 | 124.20 | 55,269.36 | 4,035.00 | https://www.sec.gov/Archives/edgar/data/1177648/000117764818000031/0001177648-18-000031-index.htm |
| 2020-01-02 | PAUL J MELLETT | Treasurer and CFO | Sell | 9,279.00 | 60.82 | 564,341.36 | 40,775.00 | https://www.sec.gov/Archives/edgar/data/1177648/000117764820000001/0001177648-20-000001-index.htm |
| 2018-09-20 | Nathalie Adda | Sr. VP & Chief Medical Officer | Buy | 2,955.00 | 43.46 | 128,424.30 | 4,155.00 | https://www.sec.gov/Archives/edgar/data/1177648/000117764818000035/0001177648-18-000035-index.htm |
| 2020-02-12 | PAUL J MELLETT | Treasurer and CFO | Buy | 1,350.00 | 41,629.00 | https://www.sec.gov/Archives/edgar/data/1177648/000117764820000007/0001177648-20-000007-index.htm | ||
| 2018-06-18 | Nathalie Adda | Sr. VP & Chief Medical Officer | Sell | 2,229.00 | 115.09 | 256,542.07 | 4,258.00 | https://www.sec.gov/Archives/edgar/data/1177648/000117764818000028/0001177648-18-000028-index.htm |
| 2020-05-05 | PAUL J MELLETT | Treasurer and CFO | Buy | 1,740.00 | 1.21 | 2,099.83 | 42,824.00 | https://www.sec.gov/Archives/edgar/data/1177648/000117764820000024/0001177648-20-000024-index.htm |
| 2018-08-20 | Nathalie Adda | Sr. VP & Chief Medical Officer | Buy | 2,955.00 | 43.46 | 128,424.30 | 4,465.00 | https://www.sec.gov/Archives/edgar/data/1177648/000117764818000033/0001177648-18-000033-index.htm |
| 2018-07-18 | Nathalie Adda | Sr. VP & Chief Medical Officer | Sell | 2,075.00 | 123.72 | 256,709.66 | 4,480.00 | https://www.sec.gov/Archives/edgar/data/1177648/000117764818000031/0001177648-18-000031-index.htm |
| 2019-02-12 | Nathalie Adda | Sr. VP & Chief Medical Officer | Buy | 4,500.00 | 4,500.00 | https://www.sec.gov/Archives/edgar/data/1177648/000117764819000015/0001177648-19-000015-index.htm | ||
| 2018-05-16 | Nathalie Adda | Sr. VP & Chief Medical Officer | Sell | 2,955.00 | 105.57 | 311,951.08 | 4,800.00 | https://www.sec.gov/Archives/edgar/data/1177648/000117764818000024/0001177648-18-000024-index.htm |
| 2019-02-12 | BRUCE L A CARTER | Director | Buy | 5,000.00 | 23.40 | 117,000.00 | 5,000.00 | https://www.sec.gov/Archives/edgar/data/1177648/000117764819000003/0001177648-19-000003-index.htm |
| 2019-12-16 | PAUL J MELLETT | Treasurer and CFO | Buy | 2,625.00 | 51,219.00 | https://www.sec.gov/Archives/edgar/data/1177648/000117764820000001/0001177648-20-000001-index.htm | ||
| 2018-07-06 | Jay R. Luly | President and CEO | Sell | 4,125.00 | 127.12 | 524,379.08 | 593,026.00 | https://www.sec.gov/Archives/edgar/data/1177648/000117764818000030/0001177648-18-000030-index.htm |
| 2018-07-06 | Jay R. Luly | President and CEO | Sell | 7,738.00 | 126.36 | 977,787.61 | 597,151.00 | https://www.sec.gov/Archives/edgar/data/1177648/000117764818000030/0001177648-18-000030-index.htm |
| 2018-04-16 | Nathalie Adda | Sr. VP & Chief Medical Officer | Sell | 2,425.00 | 85.92 | 208,354.30 | 6,000.00 | https://www.sec.gov/Archives/edgar/data/1177648/000117764818000022/0001177648-18-000022-index.htm |
| 2018-07-27 | Jay R. Luly | President and CEO | Buy | 8,498.00 | 11.77 | 99,990.02 | 601,524.00 | https://www.sec.gov/Archives/edgar/data/1177648/000117764818000032/0001177648-18-000032-index.htm |
| 2018-07-06 | Jay R. Luly | President and CEO | Sell | 7,538.00 | 125.27 | 944,264.91 | 604,889.00 | https://www.sec.gov/Archives/edgar/data/1177648/000117764818000030/0001177648-18-000030-index.htm |
| 2018-07-06 | Jay R. Luly | President and CEO | Sell | 12,622.00 | 124.26 | 1,568,460.21 | 612,427.00 | https://www.sec.gov/Archives/edgar/data/1177648/000117764818000030/0001177648-18-000030-index.htm |
| 2018-10-01 | Tim Ocain | Senior Vice President | Sell | 604.00 | 85.30 | 51,520.90 | 6,127.00 | https://www.sec.gov/Archives/edgar/data/1177648/000117764818000038/0001177648-18-000038-index.htm |
| 2019-02-12 | Jay R. Luly | President and CEO | Buy | 14,400.00 | 615,924.00 | https://www.sec.gov/Archives/edgar/data/1177648/000117764819000009/0001177648-19-000009-index.htm | ||
| 2018-07-05 | Jay R. Luly | President and CEO | Sell | 2,977.00 | 123.81 | 368,567.78 | 625,049.00 | https://www.sec.gov/Archives/edgar/data/1177648/000117764818000030/0001177648-18-000030-index.htm |
| 2018-05-17 | Jay R. Luly | President and CEO | Sell | 10,968.00 | 105.83 | 1,160,742.34 | 628,026.00 | https://www.sec.gov/Archives/edgar/data/1177648/000117764818000026/0001177648-18-000026-index.htm |
| 2019-10-08 | Jay R. Luly | President and CEO | Buy | 7,052.00 | 14.18 | 99,997.36 | 638,246.00 | https://www.sec.gov/Archives/edgar/data/1177648/000117764819000035/0001177648-19-000035-index.htm |
| 2018-05-16 | Jay R. Luly | President and CEO | Sell | 14,032.00 | 105.82 | 1,484,912.55 | 638,994.00 | https://www.sec.gov/Archives/edgar/data/1177648/000117764818000026/0001177648-18-000026-index.htm |
| 2020-02-12 | Jay R. Luly | President and CEO | Buy | 1,485.00 | 643,901.00 | https://www.sec.gov/Archives/edgar/data/1177648/000117764820000006/0001177648-20-000006-index.htm | ||
| 2019-12-16 | Jay R. Luly | President and CEO | Buy | 7,500.00 | 645,746.00 | https://www.sec.gov/Archives/edgar/data/1177648/000117764820000002/0001177648-20-000002-index.htm | ||
| 2018-06-18 | Nathalie Adda | Sr. VP & Chief Medical Officer | Sell | 1,268.00 | 113.90 | 144,426.21 | 6,487.00 | https://www.sec.gov/Archives/edgar/data/1177648/000117764818000028/0001177648-18-000028-index.htm |
| 2019-02-12 | Jay R. Luly | President and CEO | Buy | 36,000.00 | 651,924.00 | https://www.sec.gov/Archives/edgar/data/1177648/000117764819000009/0001177648-19-000009-index.htm | ||
| 2020-02-12 | Jay R. Luly | President and CEO | Buy | 8,910.00 | 652,811.00 | https://www.sec.gov/Archives/edgar/data/1177648/000117764820000006/0001177648-20-000006-index.htm | ||
| 2018-07-18 | Nathalie Adda | Sr. VP & Chief Medical Officer | Buy | 2,955.00 | 43.46 | 128,424.30 | 6,555.00 | https://www.sec.gov/Archives/edgar/data/1177648/000117764818000031/0001177648-18-000031-index.htm |
| 2018-10-01 | Tim Ocain | Senior Vice President | Sell | 14,677.00 | 84.02 | 1,233,113.11 | 6,731.00 | https://www.sec.gov/Archives/edgar/data/1177648/000117764818000038/0001177648-18-000038-index.htm |
| 2018-06-11 | PAUL J MELLETT | Treasurer and CFO | Sell | 611.00 | 122.17 | 74,647.89 | 73,458.00 | https://www.sec.gov/Archives/edgar/data/1177648/000117764818000027/0001177648-18-000027-index.htm |
| 2018-06-11 | PAUL J MELLETT | Treasurer and CFO | Sell | 5,153.00 | 121.42 | 625,658.19 | 74,069.00 | https://www.sec.gov/Archives/edgar/data/1177648/000117764818000027/0001177648-18-000027-index.htm |
| 2018-06-18 | Nathalie Adda | Sr. VP & Chief Medical Officer | Buy | 2,955.00 | 43.46 | 128,424.30 | 7,755.00 | https://www.sec.gov/Archives/edgar/data/1177648/000117764818000028/0001177648-18-000028-index.htm |
| 2018-05-16 | Nathalie Adda | Sr. VP & Chief Medical Officer | Sell | 800.00 | 104.81 | 83,844.00 | 7,755.00 | https://www.sec.gov/Archives/edgar/data/1177648/000117764818000024/0001177648-18-000024-index.htm |
| 2018-06-11 | PAUL J MELLETT | Treasurer and CFO | Sell | 6,336.00 | 120.37 | 762,655.45 | 79,222.00 | https://www.sec.gov/Archives/edgar/data/1177648/000117764818000027/0001177648-18-000027-index.htm |
| 2018-06-18 | PAUL J MELLETT | Treasurer and CFO | Buy | 6,960.00 | 1.98 | 13,798.90 | 80,418.00 | https://www.sec.gov/Archives/edgar/data/1177648/000117764818000029/0001177648-18-000029-index.htm |
| 2018-12-03 | Tim Ocain | Senior Vice President | Buy | 2,000.00 | 32.27 | 64,540.00 | 8,127.00 | https://www.sec.gov/Archives/edgar/data/1177648/000117764818000051/0001177648-18-000051-index.htm |
| 2018-04-16 | Nathalie Adda | Sr. VP & Chief Medical Officer | Sell | 1,800.00 | 85.11 | 153,205.38 | 8,425.00 | https://www.sec.gov/Archives/edgar/data/1177648/000117764818000022/0001177648-18-000022-index.htm |
| 2019-02-12 | PAUL J MELLETT | Treasurer and CFO | Buy | 4,200.00 | 84,618.00 | https://www.sec.gov/Archives/edgar/data/1177648/000117764819000011/0001177648-19-000011-index.htm | ||
| 2018-05-16 | Nathalie Adda | Sr. VP & Chief Medical Officer | Sell | 400.00 | 103.85 | 41,538.04 | 8,555.00 | https://www.sec.gov/Archives/edgar/data/1177648/000117764818000024/0001177648-18-000024-index.htm |
| 2018-06-11 | PAUL J MELLETT | Treasurer and CFO | Sell | 2,600.00 | 119.35 | 310,304.54 | 85,558.00 | https://www.sec.gov/Archives/edgar/data/1177648/000117764818000027/0001177648-18-000027-index.htm |
| 2018-06-11 | PAUL J MELLETT | Treasurer and CFO | Sell | 300.00 | 117.52 | 35,256.99 | 88,158.00 | https://www.sec.gov/Archives/edgar/data/1177648/000117764818000027/0001177648-18-000027-index.htm |
| 2018-03-19 | PAUL J MELLETT | Treasurer and CFO | Sell | 200.00 | 87.94 | 17,587.00 | 88,458.00 | https://www.sec.gov/Archives/edgar/data/1177648/000117764818000020/0001177648-18-000020-index.htm |
| 2018-03-19 | PAUL J MELLETT | Treasurer and CFO | Sell | 3,900.00 | 87.25 | 340,285.92 | 88,658.00 | https://www.sec.gov/Archives/edgar/data/1177648/000117764818000020/0001177648-18-000020-index.htm |
| 2018-05-16 | Nathalie Adda | Sr. VP & Chief Medical Officer | Buy | 2,955.00 | 43.46 | 128,424.30 | 8,955.00 | https://www.sec.gov/Archives/edgar/data/1177648/000117764818000024/0001177648-18-000024-index.htm |
| 2018-03-19 | PAUL J MELLETT | Treasurer and CFO | Sell | 3,900.00 | 86.00 | 335,412.09 | 92,558.00 | https://www.sec.gov/Archives/edgar/data/1177648/000117764818000020/0001177648-18-000020-index.htm |
| 2019-03-04 | George Golumbeski | Director | Buy | 9,280.00 | 36.61 | 339,740.80 | 9,280.00 | https://www.sec.gov/Archives/edgar/data/1177648/000117764819000028/0001177648-19-000028-index.htm |
| 2019-02-12 | PAUL J MELLETT | Treasurer and CFO | Buy | 10,500.00 | 95,118.00 | https://www.sec.gov/Archives/edgar/data/1177648/000117764819000011/0001177648-19-000011-index.htm | ||
| 2018-03-19 | PAUL J MELLETT | Treasurer and CFO | Sell | 1,000.00 | 85.05 | 85,045.50 | 96,458.00 | https://www.sec.gov/Archives/edgar/data/1177648/000117764818000020/0001177648-18-000020-index.htm |
| 2018-08-20 | Nathalie Adda | Sr. VP & Chief Medical Officer | Sell | 2,224.00 | 92.68 | 206,129.88 | 969.00 | https://www.sec.gov/Archives/edgar/data/1177648/000117764818000033/0001177648-18-000033-index.htm |
| 2019-02-13 | PAUL J MELLETT | Treasurer and CFO | Buy | 6,960.00 | 1.51 | 10,499.16 | 97,188.00 | https://www.sec.gov/Archives/edgar/data/1177648/000117764819000018/0001177648-19-000018-index.htm |